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The charge of this invited review is to present a convincing case for the fact that cells release their ATP for physiological reasons. Many of
our ‘‘purinergic’’ colleagues as well as ourselves have experienced resistance to this concept, because it is teleologically counter-intuitive.
This review serves to integrate the three main tenets of extracellular ATP signaling: ATP release from cells, ATP receptors on cells, and ATP
receptor-driven signaling within cells to affect cell or tissue physiology. First principles will be discussed in the Introduction concerning
extracellular ATP signaling. All possible cellular mechanisms of ATP release will then be presented. Use of nucleotide and nucleoside
scavengers as well as broad-specificity purinergic receptor antagonists will be presented as a method of detecting endogenous ATP release
affecting a biological endpoint. Innovative methods of detecting released ATP by adapting luciferase detection reagents or by using
‘‘biosensors’’ will be presented.
Because our laboratory has been primarily interested in epithelial cell physiology and pathophysiology for several years, the role of
extracellular ATP in regulation of epithelial cell function will be the focus of this review. For ATP release to be physiologically relevant,
receptors for ATP are required at the cell surface. The families of P2Y G protein-coupled receptors and ATP-gated P2X receptor channels will
be introduced. Particular attention will be paid to P2X receptor channels that mediate the fast actions of extracellular ATP signaling, much
like neurotransmitter-gated channels versus metabotropic heptahelical neurotransmitter receptors that couple to G proteins. Finally,
fascinating biological paradigms in which extracellular ATP signaling has been implicated will be highlighted. It is the goal of this review to
convert and attract new scientists into the exploding field of extracellular nucleotide signaling and to convince the reader that extracellular
ATP is indeed a signaling molecule.
D 2003 Elsevier B.V. All rights reserved.Keywords: ATP; Extracellular nucleotide signaling; P2X receptor channel
1. Introduction adenine compounds may have physiological activities wasTo understand autocrine and paracrine ATP signaling, the
‘‘first principles’’ of extracellular nucleotide and nucleoside
signaling must be presented. No other review in the past
spoke to all of the issues germane to extracellular ATP
signaling than the review by Gordon in 1986 [1]. This
review is modeled after that treatise, having benefited from
16 additional years of productive research as well as the
emergence of new ideas. The first evidence that extracellular0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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early study opened a new field of cardiovascular research
investigating effects of extracellular purine nucleotides and
nucleosides in blood flow. However, more than 40 years
passed before adenosine re-emerged as an important auto-
crine and paracrine mediator in extracellular signaling [3].
In 1972, Burnstock [4] postulated that ATP could act as an
extracellular signal in nerve-mediated responses of the
smooth muscles in the gastrointestinal tract and bladder.
Initially, this concept was met with considerable skepticism.
Today, we already know that extracellular signaling through
purinoceptors is vital not only in excitable cells and tissues
but also in non-excitable cells and tissues.
Newly synthesized ATP is first made and transported out
of the mitochondrion via oxidative phosphorylation. The
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the fuel for countless metabolic and enzymatic reactions.
Because ATP is essential for metabolism, release of this
precious energy substrate is met with some anxiety. Never-
theless, if one assumes that the steady-state extracellular
ATP is approximately 10 nM under basal conditions and
intracellular ATP is 10 mM, the gradient for ATP secretion
or efflux is approximately 106-fold. This gradient is 100-
fold greater, yet opposite to, the gradient for calcium entry
into cells. Naturally, if a pathway is activated or opened for
ATP release, ATP would exit the cell down a very favorable
chemical concentration gradient. However, it must be em-
phasized that only 1% or less of the intracellular ATP pool
needs to be released to activate maximally any and all
receptors. Thus, accomplishment of extracellular ATP sig-
naling can occur without compromising cellular metabolism
or essential enzymatic reactions.
Purinoceptors are divided into two classes: P1 or aden-
osine receptors and P2, which recognize primarily extra-
cellular ATP, ADP, UTP and UDP [5]. The P2 receptors are
further subdivided into two subclasses. P2X receptors are
extracellular ATP-gated calcium-permeable non-selective
cation channels that are modulated by extracellular Ca2 +,
Na+, Mg2 +, H+ and metal ions, such Zn2 + and/or Cu2 + [6].
P2Y receptors (with exception of P2Y12 and P2Y13) couple
to heterotrimeric G proteins and phospholipases (primarily
phospholipase Ch) to raise intracellular free calcium con-
centration [7]. Once released, ATP is free to bind to P2X
and P2Y receptors, on the same cell or neighboring cells.
Alternatively, ADP, a metabolite, may also bind with high
affinity to a subset of P2 receptors. UTP and UDP followFig. 1. The first principles of extracellular ATP signaling. This epithelial cell model
basolateral spaces. Intracellular ATP generated by the mitochondria creates a larg
release. Nevertheless, only 1% or less of this cytosolic ATP pool is required to be
same cell or in a neighboring cell. Not every cell in the epithelium needs to relesimilar chemistry and have their specific P2Y receptor
subtypes; however, the intracellular concentration of UTP
is micromolar rather than millimolar. The final metabolite
of ATP, adenosine, is also biologically active and binds to
P1 receptors. Once these receptors are activated, signal
transduction begins and affects cell or tissue function.
These ‘‘first principles’’ are illustrated in Fig. 1 in the
context of three neighboring epithelial cells in a polarized
epithelium.
Once ATP leaves the cell, it is also degraded rapidly;
thus, it is thought of as a local mediator that acts in an
autocrine or paracrine manner within tissues and tissue
microenvironments to stimulate its receptors before it is
chemically modified. Ecto-enzymes secreted into the ex-
tracellular milieu as a secreted protein or membrane-bound
as an ecto-enzyme target ATP. Ecto-apyrases cleave the
gamma- and beta-phosphates of ATP, yielding ADP and 5V-
AMP. Ecto-ATPases and ADPases also subserve this
function. Ecto-5V-nucleotidases can convert 5V-AMP into
adenosine, a higher-affinity purinergic agonist than ATP
for its own class of P1 G protein-coupled receptors. Like
any biochemical reaction, these can occur in reverse to re-
synthesize ATP. Secreted or membrane-bound ecto-kinases
such as adenylate kinase or nucleoside monophospho- and
diphosphokinases can phosphorylate nucleosides to re-
make 5V-AMP, ADP and, ultimately, the triphosphate
nucleotide ATP [8].
In this review, we put particular emphasis on mecha-
nisms by which ATP is released from the cells and puriner-
gic receptors and signaling in epithelial cells that transduce
that extracellular ATP signal.illustrates the first principles of extracellular ATP signaling in the apical and
e intracellular pool and an enormous gradient for ATP efflux, secretion, or
released to stimulate P2 receptors and stimulate signal transduction in the
ase its ATP; it can diffuse from a neighboring cell that released it.
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milieu
Driven by the very favorable chemical concentration
gradient for ATP secretion out of the cell, many possible
ATP release mechanisms have been postulated. Consider-
able evidence has been amassed that adenosine is trans-
ported across the membrane by concentrative nucleoside
transporters (CNTs) or equilibrative (bidirectional) nucleo-
side transporters (ENTs) [9]. By analogy, similar release
mechanisms have been entertained for nucleotides. Emerg-
ing work has also shown that adenosine is also created in
large part by extracellular metabolism of ATP. Lessons can
first be derived from the mitochondrion. Newly synthesized
ATP is transported across the inner or cisternal membrane of
the mitochondrion by an adenine nucleotide transporter
(ANT) that exchanges an ATP molecule for its metabolite,
ADP. Mitochondrial porins (also known as voltage-depen-
dent anion channels (VDACs)) conduct the ATP across the
outer membrane into the cytosol. There is considerable
biological debate about which ATP transport mechanism is
more critical for mitochondrial export.
2.1. ATP-permeable release channels
Pictured in the context of our favorite cell model (Fig. 2),
the polarized epithelial cell, ATP could be conducted
passively down its favorable chemical concentration gradi-
ent by ATP-permeable release channels. These are likely
anion channels (plasma membrane forms of VDAC or other
chloride channels) that have significant permeability to
larger anions like gluconate and ATP. These ATP release
channels could reside in the apical or basolateral membrane.
The existence of ion channels, that are permeated by ATP
anions, was underscored by many laboratories investigating
whether the cystic fibrosis transmembrane conductance
regulator (CFTR) conducted ATP itself in addition to
Cl or regulated a separate ion channel that was permeable
to ATP. One group suggested that CFTR and the multidrug
resistance transporter (mdr or P-glycoprotein) conducted
ATP [10,11]. Schwiebert et al. [12] showed that CFTR
potentiated autocrine ATP release to upregulate a separate
anion channel, the outwardly rectifying Cl channel
(ORCC). The simplest interpretation was that CFTR con-
ducted ATP; however, this group was careful to point out
that CFTR, as a conductance regulator, might also regulate
an ATP release channel, transporter, or other release path-
way [12]. Subsequently, several other laboratories failed to
show conduction of ATP through CFTR [13–16]; each
laboratory performed a limited number of experiments in
their system of choice and stopped early in their study when
the negative data mounted. Recent studies by Braunstein et
al. [17] and by Sugita et al. [18] have shown that CFTR is
likely not an ATP conductive channel itself; however, it is
closely associated with a separate ATP-permeable channel
that it regulates positively. Nevertheless, its membership inthe superfamily of ATP-binding cassette (ABC) transporters
suggests that it could transport ATP and other larger anions
non-conductively at larger rates, given the large range of
substances transported promiscuously by ABC transporters.
A handful of laboratories have performed additional
research to begin to identify ATP release pathways in cells,
to understand why CFTR would potentiate ATP release
from cells and in response to the best stimuli, and to identify
more specifically any and all ATP-permeable release chan-
nels. An initial assumption is that ATP-permeable release
channels are anion channels. ATP release assays in hepato-
cytes and cholangiocytes by Fitz et al., airway and renal
epithelial cells by Schwiebert et al., and heterologous cells
by both of these laboratories has identified the lanthanides,
gadolinium and lanthanum, as blockers of ATP release
under basal and stimulated conditions [17,19–21]. The
lanthanides are known blockers of mechanosensitive ion
channels that are permeable to cations as well as anions.
Braunstein et al. [17] has also shown that the disulfonic
stilbene, DIDS, is a blocker of ATP release that is even more
potent than gadolinium. Taken together, blockade of ATP
release in biological cells by these agents suggests that ATP
release channels are important conduits for ATP release.
One assumption is that some specific anion channels may
also be permeable to ATP. Are there likely candidates for
ATP-permeable anion channels? Thinnes et al. [22,23]
among others have documented that plasma membrane
forms of porins or voltage-dependent anion channels (PL-
VDACs) exist in a variety of cell types. In one study, they
show co-localization of CFTR with a PL-VDAC [22]. It is
known that ‘‘maxi’’ Cl channels (or large conductance
anion channels) with voltage-dependent inactivation char-
acteristics similar to VDAC have been found by numerous
investigators in numerous cell types. In fact, Fitz et al. and
Schwiebert et al. have studied such ‘‘maxi’’ anion channels
in the past in Chinese hamster ovary (CHO) cells [24,25]
and renal cortical collecting duct (CCD) cells [26,27],
respectively. Because VDAC is a major conduit for release
of newly synthesized ATP in the outer membrane of the
mitochondrion [28], an ATP-permeable VDAC in the plas-
ma membrane may be a major conductive pathway for ATP
exit into the extracellular milieu. Light, Schwiebert and
Stanton [26,27] showed that the ‘‘maxi’’ anion channel in
RCCT-28A cells, an A-type intercalated cell line from rabbit
CCD, had significant permeability to gluconate (Cl:gluco-
nate 8:1) and bicarbonate (Cl:HCO3 2:1). Sabirov et al. [29]
have shown recently that an ATP-permeable ‘‘maxi’’ anion
channel is expressed in mouse mammary carcinoma (C127)
cells. Recent preliminary work from Liu et al. [30] have
implicated a ‘‘maxi’’ anion channel in ATP release from the
macula densa induced by changes in NaCl concentration in
the cTAL. It is postulated that this ATP-permeable ‘‘maxi’’
anion channel is responsible for ATP release from the
macula densa that diffuses to and binds to P2 receptors in
the glomerulus as an important signal for tubuloglomerular
feedback, a form of single nephron ‘‘autoregulation.’’ A
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has been found in cell-attached and excised patch-clamp
recordings from non-CF and CF airway epithelial primary
cultures and cell lines and is permeable to a multitude of
different anions including ATP (E.M. Schwiebert, unpub-
lished observations). Taken together, it is clear that the
VDAC-like ‘‘maxi’’ anion channels are a leading candidate
for ATP release channels in the plasma membrane of many
cell types and tissues.
ATP-permeable anion channels may not be limited to
‘‘maxi’’ anion channels. At least two other candidates have
been implicated indirectly in published studies. These in-
clude, but are not limited to, the ORCC and the volume-
sensitive organic anion channel (VSOAC). In a study by
Braunstein et al. [17], planar lipid bilayer experiments
where bovine tracheal epithelial vesicle protein was fused
with the bilayers containing or immunodepleted of CFTR
protein. In each condition, an ATP conductance of approx-
imately 20 pS was recorded that was potentiated by hydro-
static pressure applied to the bilayer and was inhibited by
DIDS, gadolinium, and DPC. In the condition immunode-
pleted of CFTR protein, the ORCC was still present, as
determined by removing ATP-containing solutions and
replacing ATP with Cl containing solutions. The simplest
interpretation was that the 40–80 pS ORCC Cl channel
had a partial permeability to ATP. Because ORCCs may be
conferred by CLC-3 and/or CLC-5 channels (or a hetero-
meric mixture of these two CLC channels along with
additional CLC subtypes), CLC channels may also be
candidates for ATP release channels. Another, equally valid,
interpretation was that the 20 pS ATP channel was conferred
by a separate protein. Another candidate for this ATP
channel is the VSOAC channel first described and named
as such by Strange et al. In an initial characterization,
Jackson and Strange [31] showed that intracellular mM
ATP concentrations supported VSOAC currents, while
supraphysiologic external concentrations of mM ATP actu-
ally blocked macroscopic VSOAC currents carried by Cl
or by organic osmolytes such as betaine or taurine. Because
this external block was concentration- and voltage-depen-
dent, ATP can be deduced to be a possible pore blocker of
VSOAC and, thus, a partially permeable species along with
large anions such as taurine and betaine. It has been shown
that non-excitable cells, like hepatocytes, communicate via
nucleotide release [32]. ATP efflux is not uniform across a
field of cells but is restricted to abrupt point-source bursts
[33]. Transient activation of connexin hemichannels is
thought to mediate this ATP release [34].
It is important to note that these release channels may
differ in their expression as well as their polarity of
expression (if studied, in epithelial or endothelial cells or
in neurons). The next few years of work by several
laboratories should uncover much new information in the
arena of ATP release channels. Arguably, this field was
brought into the light via the controversy concerning CFTR,
mdr, and ATP permeability through these ABC transporters.Without that series of papers for and against this phenom-
enon, it is possible that this field may not have emerged this
rapidly or at all.
2.2. Adenine nucleotide transporters
Like the nucleoside transporters, concentrative or equili-
brative nucleotide transporters may also exist for ATP that
are carriers or permeases. The ABC transporters such as the
CFTR, the multidrug resistance proteins (mdr, MRP), and
the multiple organic anion transporters (MOATs) may act as
non-conductive transporters of ATP, along with a multitude
of other substrates. Exchangers may exist for ATP in the
plasma membrane, as they do in mitochondrial inner mem-
brane, where ADP may be the exchanged substrate. Other
substrates such as Na+ or Cl, which have favorable entry
gradients, may be exchanged for ATP. This could also occur
apically or basolaterally. These possible transport mecha-
nisms are also illustrated in Fig. 2.
Even though evidence is emerging that ABC transporters
do not conduct ATP at rates consistent with an ionic
channel, these transporters may transport ATP across mem-
branes at rates that may lie in a range more consistent with a
transporter. The fact that glibenclamide, tamoxifen, cyclo-
sporin A, and verapamil inhibit ATP release in several
systems underscores this possibility [35]. Indeed, Linsdell
and Hanrahan [36] have shown that CFTR transports
glutathione at rates that border channel conduction rates
(107 ions/s and above) versus transporter rates (106 mole-
cules/s or below). In fact, symport of glutathione and ATP or
ATP with another substrate could occur. KCl symporters are
critical in red blood cell and hematopoietic cell volume
regulation [37]; a KATP symporter is also not out of the
realm of possibility. Moreover, the promiscuity of ABC
transporters (mdr, MRP) and the substrates that they move
across membranes suggests that ATP could be carried along
for the ride with other countless substrates [35]. MOATs are
also possible candidates [35,38]. Investigators should keep
an open mind to this possible mechanism of ATP release.
As with VDAC or porin channels in outer mitochondrial
membrane, ANTs that transport newly synthesized ATP
across inner mitochondrial membrane to the exchange of
ADP, also play a critical role in intracellular ATP transport
[39]. Once thought to be restricted to the mitochondrion,
emerging evidence suggests that ANTs may also be
expressed in endoplasmic reticulum, the nuclear envelope
membrane, and in brain synaptic vesicles [40–42]. The
latter result suggests that ANTs may reside, at least for a
brief period of time, in the plasma membrane of neurons
once synaptic vesicles fuse to release their contents. A
reason for addressing possible expression in synaptic
vesicles is the known fact that ATP is present in high
(millimolar) concentrations along with neurotransmitters or
neuroendocrine agonists such as histamine and epinephrine.
Such exchange of ATP released into the extracellular milieu
with a metabolite of ATP transported back into the cell for
E.M. Schwiebert, A. Zsembery / Biochimica et Biophysica Acta 1615 (2003) 7–32 11re-synthesis to ATP is also a viable hypothesis. Atractylo-
side, a specific inhibitor of the ANTs, can be used as an
extracellular inhibitor of ATP release to probe the role of
ANTs in autocrine ATP release and signaling.
2.3. ATP-filled vesicle
ATP-filled vesicles, which may also contain additional
agonists or co-agonists, may fuse with the plasma mem-
brane releasing ATP. It is a known fact, dating back to the
work of Gordon [1] and Burnstock 4] and their seminal
reviews on the topic of extracellular ATP or ‘‘purinergic’’
signaling, that a high content of ATP is found in synaptic
vesicles with other neurotransmitters, mast cell granules
with histamine, and chromaffin granules with epinephrine.
ATP and its metabolites are known co-transmitters that
modulate the effect of excitatory or inhibitory neurotrans-
mitters. ADP and ATP are also released by platelets on their
own via exocytosis for a ‘‘self-aggregation’’ signal at the
clotting zone. Release of ATP-filled vesicles is the principal
transmitter signal for ‘‘purinergic’’ nerves in the gut, the
nociceptive nodose neurons in the dorsal root ganglia of the
spinal cord, and in specialized nerves in the brain. Thus,
exocytosis of ATP-filled vesicles, preformed and poised to
fuse beneath the plasma membrane, should be considered as
a major release mechanism. One critical question regarding
the presence of ATP in vesicles is: how does the ATP
become loaded and concentrated in these vesicles to high
millimolar concentrations? We hypothesize that ATP chan-
nels and transporters may function to transport or load ATP
into these vesicles and concentrate the ATP within. As an
anion, ATP transport into the vesicle could be facilitated by
H+-ATPases, which would transport and concentrate H+ inFig. 2. Possible ATP release mechanisms in apical and basolateral membranes of po
present in each membrane domain that are likely anion-permeable channels. P
candidates. Adenine nucleotide transporters may also exist that may be carriers or
nucleotide/nucleoside exchangers are located in the mitochondrial membrane and m
be present in epithelia as they are in neurons, neuroendocrine cells, mast cells, anthe vesicle lumen. ATP would follow to preserve macro-
scopic electroneutrality across the vesicle membrane. It is
important to note that, once a vesicle fuses and release its
quanta of ATP, that ATP channels and/or transporters would
then be inserted and present in the plasma membrane to
drive ATP release further. These are the same channels and
transporters that served to load the vesicle before its fusion.
The potential issues surrounding the loading, fusion, and
release of ATP from secretory vesicles is shown in Fig. 2.3. Innovative methods to detect autocrine ATP release
and signaling
3.1. Indirect pharmacological screening for extracellular
nucleotide and nucleoside release and signaling: nucleotide
and nucleoside scavengers
A potent and effective way of blocking autocrine and
paracrine signaling by nucleotides and nucleosides is with
inclusion of scavengers for purinergic agonists. Hexokinase
(with inclusion of 5 mM glucose) will scavenge ATP in
preparations, yielding ADP and donating the terminal or
gamma phosphate of ATP to glucose forming glucose-6-
phosphate. This maneuver eliminates ATP from solutions
and prevents any endogenous ATP released in cell or tissue
preparations from interacting with P2 receptors that prefer
ATP. ADP is a better agonist at some P2Y receptors and a
weak agonist for some P2X receptors. As such, in lieu of
hexokinase, apyrase, an ATPase/ADPase, would eliminate
ATP and ADP from solutions rapidly. However, apyrase
generates 5V-AMP, a precursor of adenosine activating P1
adenosine receptors. Thus, a final maneuver is the inclusionlarized epithelia. From left to right: ATP-permeable release channels may be
lasma membrane forms of the mitochondrial porins or VDACs may be
permeases not unlike the ABC transporters, CFTR, mdr, or MOAT. Adenine
ay also be expressed in the plasma membrane. ATP-filled vesicles may also
d platelets.
E.M. Schwiebert, A. Zsembery / Biochimica et Biophysica Acta 1615 (2003) 7–3212of adenosine deaminase, which converts active adenosine
into inert inosine.
3.2. Indirect pharmacological screening for extracellular
nucleotide and nucleoside release and signaling: global P2
and P1 receptor antagonists
An alternative maneuver to prevent autocrine or para-
crine activation of purinergic receptors are non-selective or
global antagonists that block most if not all P2 or P1
receptors. The best approach for broad blockade of P2
receptors is suramin. It is noteworthy, however, that suramin
poorly inhibits certain P2X receptor subtypes, is also a weak
antagonist for growth factors, and may also block other
classes of calcium entry channels besides P2X receptor
channels. In this case, pyridoxal phosphate-6-azophenyl
2V,4V-disulfonic acid (PPADS) can be used together with
suramin in a cocktail. Nonetheless, both PPADS and sur-
amin are ecto-nucleotidase inhibitors complicating their use
in indirect assays [43]. In addition, PPADS and trinitro-
phenyl-ATP (TNP-ATP), another P2X-selective agonist,
change the color of the Ringer’s solution and cannot be
used in fluorescence experiments.
A similar approach can be taken for adenosine receptors.
CPX (also known as DPCPX or 8-cyclopentyl-1,3-dipropyl-
xanthine) is a broad specificity antagonist of P1 receptors.4. Novel and direct assays to detect ATP release from
cells
Ultimately, direct measurement of extracellular ATP in
solution is the preferred course of action to study whether a
cell or tissue is releasing ATP in a physiological or biological
manner. There has been a recent revolution in the establish-
ment of assays that can detect extracellular ATP signaling in
cells and tissues. This has involved either adaptation of the
luciferase/luciferin bioluminescence detection assay from
the test tube to ‘‘sense’’ ATP release in biological prepara-
tions, the linkage of luciferase to cells via protein A and
epitope antibodies to ‘‘sense’’ ATP release in the cell surface
microenvironment, the development of the PC-12 pheochro-
mocytoma cell as a ‘‘biosensor’’ that can measure ATP, and
the invention of an atomic force microscopy (AFM) probe
coated with myosin or luciferase to ‘‘sense’’ ATP.
4.1. Assays to detect ATP release: luciferase/luciferin
bioluminescence detection
Firefly and Renilla luciferase and luciferin have been
used for decades to measure ATP in preparations. Labora-
tories have taken aliquots of extracellular solution bathing
cells and tissues, mixed these samples with luciferase and
luciferin, and measured bioluminescence in a multi-step
process. This has yielded much interesting and novel
information. However, many laboratories have gone a stepfurther and included the luciferase/luciferin detection
reagent directly into the medium or solution bathing the
cells, cell monolayer, or tissue and measured ATP release.
Schwiebert et al. developed such an assay for detecting
or ‘‘sensing’’ ATP release in real-time from non-polarized
cells and more importantly, for polarized epithelial and
endothelial cell monolayers grown on filter supports
[17,19,21,44,45]. The same real-time assay has been used
extensively by Fitz et al. to study ATP release from
hepatocytes and cholangiocytes [20,35,46,47]. Both labora-
tories have demonstrated that cells release ATP constitu-
tively under basal or unstimulated conditions and elevation
of cyclic AMP (cAMP), increases in cytosolic calcium, and
hypotonic challenge trigger further ATP release, while
hypertonicity inhibits ATP release. Via this assay, it was
shown that ATP release and signaling is lost in the apical
microenvironment of CF monolayers versus controls
[17,19], while ATP release and signaling in polycystic
kidney disease (PKD) monolayers was as great or greater
in the apical microenvironment and greater in the basolateral
environment [21,44].
A groundbreaking study has applied luciferase/luciferin
bioluminescence detection technology to a tissue prepara-
tion. Sorensen and Novak [48] used confocal imaging of the
bioluminescence generated from ATP being catalyzed by
luciferase. They studied individually dissected pancreatic
acini to measure ATP release and signaling in this ‘‘in vivo-
like’’ preparation. They showed elegantly that mechanical
stimuli, hypotonic challenge, and carbachol, an agonist that
increases cytosolic calcium in this tissue, all increased ATP
release. They were also able to show intracellular ATP store
depletion through caged ATP as well as quinacrine, which
labeled a similar ATP pool. It was estimated that ATP
release upon cholinergic stimulation generated an ATP
concentration of 9 AM in the acinus. It was postulated that
this acinus-derived ATP not only could modulate acinar cell
function in an autocrine manner but could also diffuse to the
pancreatic ducts in acinar secretions to stimulate P2 recep-
tors in a paracrine fashion. This laboratory, as well as our
own, are trying to take this technology to more in vivo-like
tissue preparations to relate the in vitro findings in cultured
cell monolayers to freshly dissected tissues. One important
issue is cell damage during the dissection. Novak et al.
showed elegantly via multiple lines of evidence that this
possibility was eliminated carefully in their work.
A limitation of the above methods of extracellular ATP
‘‘sensing’’ or detection is the fact that the luciferase/luciferin
detection reagent is solubilized in the solution or medium;
however, because of unstirred layers both in the cell cultures
and cell monolayers in vitro and the freshly dissected
tissues, the assay may miss ATP released into the microen-
vironment immediately above the cell surface. Beigi et al.
[49] were aware of this issue and the fact that the ATP might
be degraded by ecto-ATPases (ecto-apyrases) on the cell
surface before it could be detected in bioluminescence
assays. As such, they used molecular biology to develop a
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through protein A chemistry, could be linked to any anti-
body that could be bound to an extracellular epitope of any
cell surface antigen, usually a transmembrane protein. They
took advantage of the fact that many extracellular epitope
antibodies have been created for cell surface antigens on
hematopoietic cells. They showed that they could detect
micromolar amounts of ATP being released under basal
conditions and that inhibition of ecto-ATPases could pro-
long the bioluminescence signal. Theoretically, this lucifer-
ase/protein A conjugate could be targeted to any cell surface
antigen that had a well-characterized and high-affinity
antibody that recognized an extracellular epitope. Targets
may include CFTR or other ABC transporters implicated in
the facilitation of ATP release, CD39 and other ecto-
ATPases where the competition between degradation and
detection could be studied, or P2 receptors themselves to
sense what the local ATP concentration is at the receptor
when it is engaged and activated.
4.2. Assays to detect ATP release: ‘‘biosensors’’
Hazama et al. used much ingenuity in developing a
technique where the PC-12 cell, a pheochromocytoma cell
line was exploited to be used as a ‘‘biosensor’’ because it
expressed the P2X2 receptor and, possibly, other P2 recep-
tors as well [50]. The initial paradigm developed involved
establishing a whole cell path-clamp recording designed toFig. 3. Schematic summary of current real-time detection methods for released ATP
where a conformational change and/or heat generated from the reaction (catalyzed
to an extracellular epitope IgG antibody at the cell surface or lyophilized luciferas
used to detect released ATP in real-time within a luminometer or by microscopic im
clamp configuration also can detect released ATP through activation of its endogrecord to P2X receptor channel currents. Then, the PC-12
cells was detached from the substrate (PC-12 cells do not
attach well to tissue culture plastic as it is), and a single PC-
12 cell, still in whole cell configuration, was moved into
close proximity with a cultured cell of interest. If P2X
receptor channels opened and current was recorded, then
this would suggest that the cultured cell was releasing ATP.
Hazama et al. [50] did this originally with pancreatic h cells
to show that micromolar ATP was released along with insulin
in response to glucose. Hazama et al. [51] have also applied
this assay to non-CF versus CF cells as well as intestinal 407
cells. They have shown that ATP release is impaired in CF
cells or in cells lacking CFTR when compared to controls.
Liu et al. [30] have extended this assay to study macula
densa signaling in an in vivo-like preparation. Peti-Peterdi
in Bell’s group dissects nephron preparation in which the
cTAL with the small patch of macula densa cells is attached
to the glomerulus of the same nephron. Using the PC-12
‘‘biosensor’’ cell either in whole cell patch-clamp mode or
loaded with Fura-2 to measure calcium influx through P2X
receptor channels, this group has shown that ATP is released
from the serosal or basolateral aspect of the macula densa
cells. Patch-clamp evidence suggests the presence of a maxi
anion channel with significant permeability to ATP as the
principal ATP release mechanism in macula densa. As with
the AFM method below, the PC-12 cell ‘‘biosensor’’ method
provides a probe that could be used in many other cultured
or freshly dissected tissue culture preparations.. From left to right: AFM probe coated with a myosin fragment or luciferase
by ATP) causes tip vibration. Luciferase linked to protein A and conjugated
e/luciferin reagent resuspended in the medium bathing a monolayer are also
aging. A PC-12 cell loaded with Fura-2/AM or held in the whole cell patch-
enous, extracellular ATP-gated P2X2 receptor.
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by Schneider et al. [52] for real-time ATP measurements,
which allows for the direct detection of ATP on the surface
of living cells. This sensor incorporates ultra high surface
topography measurements using the principles of AFM and,
at the same time, allows one to scan for changes in ATP
concentrations only angstroms from the surface of cells.
With the implementation of this new technology, one can
obtain accurate and reproducible recordings from living cells
of both the topography and surface ATP concentrations in
real-time. By developing the concept of a biosensor attached
to the surface of an AFM cantilever, it is now possible to
generate specific biosensors that can probe the surface
environment of living cells under resting and experimental
conditions and record changes in both the topography and
the microenvironment surrounding the cell membrane.
Using this assay, Schneider et al. [52] were able to
demonstrate that CF airway cells stably complemented with
wild-type CFTR released ATP, measured as localized
changes in ATP concentration. These changes in ATP
appeared as lines across the surface of the cells that were
actively secreting ATP. This aspect was intriguing to this
group, as one might have expected that the cell would have
single ‘‘hot spots’’ where the ATP was being released. By
calculating the small volume that the tip actually occupies,
we could determine that we would need around four
molecules of ATP to be present to activate the tip [52]. As
it is now possible to attach biologically active molecules to
the tip of the AFMP, it may now be possible to develop a
series of ‘‘biosensors’’ that can detect other reactive efflu-
ents from cells. This group is currently developing a tip that
would allow incorporation of luciferase on the surface of the
tip. This would allow one to detect relative changes in
fluorescence of the tip as well the deflection of the probe
due to the heat generated by the luciferase reaction. One
could then directly calculate the level of ATP being released
per unit time (J.P. Geibel, personal communication).
Fig. 3 summarizes the known approaches to detection of
released ATP in cell and tissue preparations. In our view,
multiple approaches are prudent to validating that autocrine
and paracrine nucleotide signaling is occurring in a prepa-
ration. Often, this includes pharmacological blockade of
purinergic signaling along with luciferase-based detection of
the released nucleotide.5. Heptahelical nucleotide-activated G protein-coupled
receptors (P2YRs)
Early work, primarily in the cardiovascular system,
recognized first the potent extracellular actions of ATP
and adenosine [2]. Burnstock [4,53] later identified and
proposed the concept of ‘‘purinergic’’ nerves and ‘‘puriner-
gic’’ receptors. The early classification proposed two major
groups, P2 receptors (for ATP as the agonist) and P1
receptors (for adenosine as the agonist) [54]. Subsequently,rank order potency profiles with different nucleotides and
nucleotide analogs (as well as nucleoside and nucleoside
analogs) revealed distinct pharmacological subtypes for the
P2 and P1 subgroups. For example, P2U (later renamed
P2Y2) was characterized by UTP as its best agonist.
Permeabilization of cells by ATP and other nucleotide
agonists was classified as being mediated by the P2Z and/
or P2X receptors. P2T was a receptor classified early on in
thrombosis by platelets. It has still not been identified at the
molecular biological level. P1 receptors were quickly split
into two groups: A1 (for adenosine receptors that couple via
G proteins to phospholipases) and A2 (for adenosine recep-
tors that couple via G proteins to adenylyl cyclases).
The P2Y family of heptahelical or serpentine receptors is
well characterized and has been reviewed extensively. The
reader is referred to many seminal reviews on P2YRs for
more detailed information [55–63]. Extracellular ATP-gated
P2X receptor channels will be dealt with in detail below.
Rank order potency of agonists has always been the first
method of differentiating P2YR subtypes. It was and still is
an imperfect science. However, in the absence of a large
array of selective agonists and a total absence of selective
antagonists, it was all purinergic receptor laboratories had in
their arsenal. Molecular biology verified this imperfect
science, when the P2Y1 and P2Y2 receptors were cloned.
In the old nomenclature, the P2YR (later renamed P2Y1)
was classified as being activated equally well by ATP and
ATP analogs as well as ADP and ADP analogs. The analogs
that were most effective were 2-methylthio ATP (2-MeS-
ATP) and 2-MeS-ADP as well as ATPgS and ADPhS. Very
recently, two new antagonists have been developed that are
selective for P2Y1, MRS 2179 and MRS 2269 [55]. P2Y1
(together with P2Y12) remains a candidate for being the
actual P2T receptor on platelets, because ADP is the major
co-agonist with thrombin that promotes platelet self-aggre-
gation. The P2Y2 receptor (P2UR in the old nomenclature)
is identified by its equal or greater affinity for UTP and
UTPgS versus ATP, while ADP, UDP and diphosphate
analogs are ineffective. This became a less perfect diagnos-
tic tool when the P2Y4 receptor was cloned and character-
ized. P2Y4 also binds UTP, UTPgS, and ATP. In contrast,
P2Y6 binds UDP with higher affinity than any other agonist.
P2Y3 is a species homolog of P2Y6. More recently, P2Y11,
P2Y12, and P2Y13 were identified by homology cloning and
were verified to be nucleotide receptors [64]. Interestingly,
the UDP-glucose receptor that was originally cloned from
human myeloid cells is structurally related to the P2Y
receptors. Thus, this receptor has been tentatively included
in the P2Y receptor family as P2Y14 [65]. However, the
pharmacology is quite broad again for these receptors and
exhibits a similar profile to the P2Y1 receptor. Verification
of nucleotide receptors is an important point, because cDNA
clones with significant homology to known G protein-
coupled nucleotide receptors have subsequently been char-
acterized and found not to be nucleotide receptors. These
include P2Y5, P2Y7 (found to encode the leukotriene B4
Fig. 4. Illustration of the P2Y receptor subtype classification. The imperfect science of using nucleotides or nucleotide analogs to decipher the presence of
different P2Y subtypes is shown in this cartoon. Only UDP is really truly selective for P2Y6. P2YRs can be dissected better from P2XRs and P1Rs by virtue of
their signal transduction cascades (PLC= phospholipase C; AC= adenylyl cyclase) and the nature of the receptor-mediated increase in cytosolic calcium.
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fact that there are hundreds of known heptahelical receptors
in the G protein-coupled receptor superfamily, some of
which are still ‘‘orphan’’ and searching for an agonist.
Nevertheless, in our laboratory, we probe for P2YRs by
using UTP (for P2Y2 and P2Y4), UDP (for P2Y6), and ADP
(for P2Y1, P2Y11, and P2Y12).
Despite the wide-ranging and non-specific pharmacolo-
gy, P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 share a common
signal transduction pathway involving heterotrimeric Gq
protein, phospholipase Ch, endoplasmic reticulum-depen-
dent Ca2 + mobilization and activation of protein kinase C.
In contrast, P2Y12, P2Y13 and P2Y14 are Gi-coupled recep-
tors and do not trigger increase in cytosolic Ca2 + concen-
tration but do activate a host of Gi-initiated signaling
cascades. It is interesting to note that P2Y11 receptors can
directly activate adenylyl cyclase and cAMP accumulation
[66]. Fig. 4 illustrates the subclassification of P2Y G
protein-coupled receptors. P1 adenosine receptors are also
shown to be thorough. A brief summary of their classifica-
tion and properties is included in this figure as well. For
details concerning adenosine receptors, the reader is referred
to recent reviews [60,67,68].6. Extracellular ATP-activated ion channels (P2XRs)
6.1. Background
The fact has been known for decades that application of
ATP as an extracellular agonist on a cell or tissue led to
‘‘permeabilization’’ of the cell plasma membrane. Therewere many interpretations of this phenomenon, although a
role in exacerbation of cell injury was a common conclu-
sion. The receptors thought to underlie this effect were
classified as the P2Z receptors in the early nomenclature
and were thought to be a subtype of the P2Y family. P2X
receptors were first distinguished from P2Y receptors based
on pharmacological criteria by Burnstock and Kennedy in
1985 [69]. This early subdivision of P2 receptors was later
validated based on molecular cloning and second messenger
system of P2X and P2Y families [70].
In seminal papers and reviews about this original elec-
trophysiological research on native cells, Bean et al. [71–
74] showed that single channel conductances of as little as 1
picoSiemen (pS) to as large as 100 pS could be observed
upon addition of ATP agonists. The different channels also
had different biophysical current signatures, with differing
kinetics, dependence on voltage, and rate of inactivation
(later determined to be desensitization). The permeability of
the channels to monovalent and divalent ions also varied.
This was exceedingly frustrating, because the variability in
the recordings often made this research difficult to decipher.
Moreover, this issue of ATP permeabilization of cells
always loomed in the background as a troubling issue. In
hindsight, a subset of these channels were indeed P2XRs of
varying types and, possibly, different multimeric mixtures.
Other channels recorded immediately after ATP stimulation
may have been separate ion channels that P2XRs and,
possibly, P2Y G protein-coupled receptors, were stimulating
via rapid signal transduction mechanisms.
There were also physiological reasons for believing that
extracellular ATP-gated ion channels existed. Burnstock [4]
proposed the existence of so-called ‘‘purinergic nerves’’ in
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ergic nor adrenergic. By inference, the ATP that was
released from the synapse had to bind to a receptor channel
to propagate the action potential. Moreover, the ATP that
was applied to whole cell patch-clamp and voltage-clamp
preparations activated ion channels as rapidly as activation
observed in the acetylcholine receptor channel in neurons
and muscle. There was also a relative potency of different
nucleotide agonists in the rapid activation of these ion
channels, suggesting that this was a receptor-mediated effect
that had physiological meaning.
6.2. Molecular identity
This physiological work has now been validated by
molecular biology. At least nine P2X receptor channel
subtypes (P2XRs, as we will refer to them) have now been
cloned, identified, and characterized [75–83]. Other tissue-
specific [84] and developmentally regulated P2XRs [85,86]
are still emerging, as are P2XRs from lower model organ-
isms such as zebrafish [87–89]. Transgenic knockout of
P2XR genes has begun in an effort to understand their
physiological roles more thoroughly. Mice lacking P2X1
receptor channels expressed one major phenotype, reduced
fertility due to lack of ejection of sperm from the testes into
the vas deferens [90]. The interpretation was that P2X1
receptors are the main purinergic receptor on testes and vas
deferens vascular smooth muscle cells. The sympathetic-
driven contractile response is mediated in large part by
P2XRs; however, this study showed that P2X1 was the
principal postsynaptic receptor channel involved. Fertility
was reduced by 90% in homozygous knockout mice, but not
in wild-type or heterozygous mice, not because of defects in
spermatogenesis, but in ejection of sperm through the vas
deferens into the ejaculate [90]. Any other phenotypes in the
mice were subtle and not detected as yet in this study.
Vlaskovska et al. [91] have generated a P2X3-knockout
mouse. With this mouse, this laboratory has shown that two
different populations of sensory neurons are impaired in
their function due to a lack of P2X3 [91,92]. The subur-
othelial plexus of the mouse bladder showed abundant
staining for P2X3. Although ATP was released similarly
in response to bladder distension in P2X3 +/+ versus P2X3
 / mice, the bladder afferent nerve activity was attenu-
ated in response to distension [77]. The loss of this activity
in the P2X3  / mice could be rescued by exogenous
ATP analogs or ATP itself, while normal activity in the
P2X3 +/+ afferents was blocked by TNP-ATP, PPADS, and
capsaicin [91]. These data suggest that P2X3 is a major
neural sensory receptor on a population of bladder nerve
fibers that transduce bladder distension into an electrical
signal. Specialized neurons of the dorsal root ganglia
respond to ATP as a principal neurotransmitter by a mech-
anism that is transduced by different P2XR subtypes, P2X2,
P2X2/P2X3 heteromultimers, and P2X3. Zhong et al. [92]
also examined the activity of DRG and nodose neurons(specialized neurons of the DRG involved in pain percep-
tion) in P2X3  / mice. Because P2X3 has a distinctive,
rapidly desensitizing response to ATP, patch-clamp electro-
physiology of the neurons was employed to look for
differences between P2X3 +/+ and P2X3  / cells. All
P2X3  / DRG neurons failed to desensitize after ATP
stimulation, and both subsets of neurons failed to respond to
ah-methylene ATP. The responses that were persistent in
the P2X3  / neurons were consistent with intact, en-
dogenous expression of P2X2. These studies showed that,
although DRG and nodose neurons remained responsive to
ATP, the nature of the neuronal sensory response to the ATP
neurotransmitter in the spinal cord is significantly altered
and more long-lived.
6.3. A member of the two transmembrane-spanning cation
channel superfamily
P2XRs were assumed to be a subtype of the heptahelical
P2Y family. Instead, P2XRs were predicted to form two
transmembrane-spanning ion channels with intracellular N-
and C-termini. Once more, two-thirds of the molecular mass
of this protein was predicted to be extracellular. This overall
structure made P2XRs closely related to the ENaC/degen-
erins family of cation channels found in mammalian cells
and in the nematode, C. elegans [93–95]. Fig. 5 illustrates
this similarity. In the extracellular domain of each cation
channel family, 10 conserved cysteines are found in P2XRs,
while 14 conserved cysteines are found in the ENaCs. Each
extracellular domain is highly glycosylated, with at least
three putative glycosylation sites [93–96]. This large extra-
cellular domain, which accounts for two-thirds of the
molecular mass of P2XRs, is shared by P2XRs and ENaCs;
however, this domain is divergent from the large family of
inwardly rectifying K+ (IRK) channels. P2X2 and aENaC
appear to share the PPXXY motif that is mutated in Liddle’s
disease in aENaC and is a recognition site for ubiquitination
[93,95]. What is still unclear in both P2XR and ENaC
families is the amino acids critical to the cation channel
pore. Extracellular to the second transmembrane domain of
ENaC is a putative H2 domain that has a GGQLG sequence
that is somewhat similar to the GYG motif found in the P
loop (equivalent to H2 domain) of two transmembrane-
spanning IRK channels. P2XRs are not thought to have a P
loop; however, recent alignment of the sequences of P2XRs
did reveal a GVG motif in the second transmembrane a-
helix of all P2XRs except P2X7 [97]. It is important to note
that there is little or no overall nucleotide sequence homol-
ogy between any P2XR subtype and any ENaC subtype,
despite the very similar structural characteristics.
The similarities in topology of P2XRs and ENaCs also
extend to their cell physiology. As members of the two
transmembrane-spanning ion channel superfamily (see
above), P2XRs were long suspected to form homomultimers
or, in some cell models, heteromultimers of mixed P2XR
subtypes. ENaCs form fully functional amiloride-sensitive
Fig. 5. Close and detailed comparison between P2XRs and ENaCs. These two transmembrane-spanning cation channel subfamilies exhibit similarity in their
topology and, possibly, their overall structure. Other biochemical and cell biological similarities are listed, keeping in mind that there is little or no overall DNA
or amino acid sequence homology. One major difference is the fact that the cation permeability/selectivity of each subfamily is very different.
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ahg-ENaC heteromultimer [93,95]. Torres et al. [98–101]
explored multimerization elegantly with parallel biochemi-
cal and physiological methods in the HEK-293 cell heter-
ologous cell system with multiple studies. The most elegant
of these studies was the examination of the ability of all
P2XR subtypes to oligomerize or multimerize [99]. Co-
immunoprecipitation of epitope-tagged P2XRs was under-
taken to probe the ability of P2XRs to form homomultimers
and heteromultimers. HA and FLAG biochemical tags
added to the C-terminus of each P2XR subtype did not
affect cation channel function or other properties such as
desensitization. The exception in this work was P2X6,
where even the wild-type construct failed to generate cation
currents. Again with the exception of P2X6, all other P2XRs
tested (P2X1 through P2X5 and P2X7) were capable of
forming homomultimers. The authors maintain that the
inability of P2X6 to form oligomers may explain why it
also fails to form functional channels. The stoichiometry of
these multimers is unknown; however, dimers, trimers, and
tetramers have been postulated [99]. With regard to hetero-
multimers, all P2XRs were capable of forming multimeric
complexes with other subunits, with the notable exception
of P2X7. A helpful table in this paper [99] summarizes
which P2XR subtypes oligomerize with specific other
P2XR subtypes. P2X1 and P2X2 co-assemble with them-
selves as homomultimers and with P2X3, P2X5, and P2X6,but not P2X4 or P2X7. P2X3 co-assembles with P2X1,
P2X2, and P2X5, but not with P2X4, P2X6, or P2X7.
P2X4 expressed at very high levels in the HEK-293 cell
system, making it difficult to assess in this analysis relative
to the other subtypes. However, when the conditions were
made favorable, P2X4 was found to oligomerize only with
itself and with P2X5 and P2X6. This result was very helpful
to our laboratory, which found that P2X4 and P2X5 were
most abundantly expressed in human vascular endothelial
cells and in human and rodent airway, gastrointestinal, and
kidney epithelial cell models. There is some preliminary
evidence emerging from other laboratories that P2X6 may
also be a prominent epithelial subtype. Unfortunately, the
lack of an antibody and the lack of an ability for our
degenerate RT-PCR to detect P2X6 has not allowed us to
assess its expression. P2X5 co-assembled with every other
P2XR subtype, except P2X7. P2X6 co-assembles with
P2X1, P2X2, and P2X4, but fails to interact with P2X3,
itself, or P2X7. These seminal results solidify a plethora of
the functional studies [98,99,101–106] that show physio-
logical evidence for heteromultimeric assembly of unique
pairs of P2XR subunits.
6.4. P2XR biophysics
There is a profound difference between P2XRs and
ENaCs with regard to selectivity of cation permeation.
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selective cation channel ever described. In sharp contrast,
P2XRs are non-selective cation channels for monovalent
and divalent cations. P2XRs are calcium-permeable non-
selective cation channels that, like the glutamate, NMDA,
and kainate receptor channels at excitatory synapses, are
gated by an extracellular agonist, show divalent and mono-
valent permeation, and divalent cation block. P2XRs are
thought to trigger signaling by mediating calcium influx
from extracellular stores and by changing the plasma
membrane potential; however, other signaling mechanisms
may be governed by ATP-gated receptor channels. P2XRs,
as well as the P2Y G protein-coupled receptors, also
stimulate other ion channels in native cells, complicating
their definition in specific cell models.
Ding and Sachs [107] studied elegantly the biophysics of
the P2X2 channel protein, expressed in HEK-293 cells
devoid of endogenous P2XRs when maintained as isolated
cells. Outside-out patches were performed so that the ATP
agonist had free access to the extracellular domain of the
receptor channel protein. While monovalent cations were
permeant in a sequence that was K+>Rb+>Cs+>Na+>Li+,
divalent cations also entered the pore. However, divalent
cations such as Mn2 +, Mg2 +, Ca2 +, and Ba2 + also blocked
the channel in a manner characterized as ‘‘fast block,’’
reducing the amplitude of the single channel currents.
Importantly, organic cations such as NMDG+, Tris+,
TMA+, and TEA+ were virtually impermeant. The channels
were ‘‘flickery,’’ in that they opened in brief bursts. The
single channel conductance was 49 pS in the presence of K+
and 35 pS in the presence of Na+. P2XR Na+ currents were
partially blocked by Mg2 + and Ca2 +. A subsequent paper
showed that divalent cations also speeded inactivation of the
P2X2 channels [108].
6.5. Key amino acid residues within P2XRs
Site-directed mutagenesis has been used to probe many
regions critical to the activity of P2XR channels. With
regard to cation permeation through the pore, 5 amino acid
residues in a 20-amino acid stretch corresponding to the first
transmembrane a-helix (H33, R34, I50, K53, and S54) were
implicated in cation binding and permeation within the
P2X2 receptor channel [109,110]. Another study of P2X2
channels in HEK-293 cells probed a larger stretch of amino
acids flanking and within the first transmembrane segment
[111]. Their cysteine-scanning mutagenesis revealed that
D15, P19, V23, V24, G30, Q37, and F44 were involved
in cation binding and permeation. Migita et al. [112] also
probed the second a-helical transmembrane domain for
residues key in divalent cation binding and conduction
through P2XRs. Ca2 + permeability through P2X2 expressed
in HEK-293 cells was thought to be mediated by amino
acids with negatively charged side chains, D315 and D349.
This had no effect on divalent cation permeation. Rather, the
size of side chains that were exposed to the pore of thechannel was critical. Mutation of polar threonines at posi-
tion 336 and 339 as well as a serine 340 affected cation
permeation profoundly. The largest changes were induced
by replacement of these residues with a tyrosine, whose
bulky side chain prevented Ca2 + movement altogether.
Taken together, these three studies by Egan and Voigt and
one study by North et al. showed that the two transmem-
brane a-helices cooperate in conduction of monovalent and
divalent cations through the pore.
In addition to the evidence generated by Haines et al.
[109] regarding ATP gating of the channel by binding to the
extracellular face of the first transmembrane segment, Jiang
et al. [113] also addressed this issue in the P2X2 receptor
expressed in HEK-293 cells. Alanine-substitution mutagen-
esis on 30 polar residues in the presumptive extracellular
domain revealed two positively charged lysine residues
(L69 and L71) near the same region proximal to transmem-
brane domain 1 implicated by Egan and Voigt. Substitution
with cysteines for these lysines and other flanking amino
acid residues showed similar effects. These experiments also
implicated S65 and I67 in ATP binding and gating of the
P2X2 channel. In particular, I67 was identified to be critical
to the ATP-binding site [113]. Perhaps, anionic ATP is
attracted to and bound by these lysines and the flanking
serine and isoleucine help stabilize this interaction. Upon
binding, ATP may also mask these closely coupled lysines
with positively charged side chains, removing steric hin-
drance and allowing cations to move from the external
channel vestibule into the pore. Ennion et al. [114] studied
the extracellular domain of the P2X1 receptor, searching for
residues critical for ATP binding. This study and the one
above came out concurrently. They too targeted conserved
lysines and arginines, postulating that positively charged
side chains might attract and/or bind anionic ATP. Many
were irrelevant; however, like the P2X2 receptor studies
above, K68 and K70 external to transmembrane domain 1
and R292 and K309 external to transmembrane domain 2
were key to ATP recognition. Taken together, these two
studies on different P2XR subtypes show that the ATP
binding pocket is indeed at the extracellular face of the
cation pore close to the channel vestibule.
P2X1 and P2X3 receptor channels desensitize rapidly
upon binding ATP and opening, while the other major
subtypes (P2X2 and P2X4 through P2X7) inactivate slowly
or not at all. Koshimizu et al. [115] swapped a stretch of six
amino acids of P2X3 and for P2X4 with the corresponding
stretch of arginine 371 through proline 376. P2X4 sequence
substitution slowed receptor desensitization, while P2X1
and P2X3 sequence substitution caused rapid desensitiza-
tion. Co-expression of P2X2 and P2X3 caused a phenotype
that had delayed desensitization, a phenotype intermediate
to P2X2 and P2X3 expressed alone. Thus, this highly
charged stretch of amino acids in the C-terminus plays a
significant role in desensitization. Boue-Grabot et al. [116]
identified a protein kinase C phosphorylation site, TX(K/R)
at amino acids 18 through 20 in the N-terminus of the P2X2
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Normally, a slowly or poorly desensitizing P2X subtype,
mutation of the N-terminus of P2X2 (T18A, T18N, or
K20T) showed rapid desensitization. Phosphorylation of
this site within the N-terminus was verified biochemically.
Examination of the N-terminal sequences of all P2X sub-
types reveals that P2X1 and P2X3, rapidly desensitizing
subtypes, lack this threonine at position 18, while the other
more slowly desensitizing subtypes possess this conserved
PKC site. Still another laboratory generated data suggesting
that the hydrophobic transmembrane segments were critical
in desensitization [117]. Chimeric swapping of the TM
domains from P2X1 and P2X3 with P2X2 affected desen-
sitization markedly. Taken together, these results suggest
that all regions of the P2X receptor accessible to the cytosol
are involved in receptor desensitization following ATP
binding and channel opening.
6.6. Wide and robust expression of P2XRs
P2XR subtypes are expressed abundantly in brain and
spinal cord, and the most comprehensive analysis of their
relative expression in these tissues was from Collo et al.
[82]. The functional role of P2XRs in different excitable cell
preparations will be addressed in more detail below. It was
once thought that P2XR expression was restricted to excit-
able cells. Although the P2XR as an excitatory postsynaptic
receptor channel is easy to envision and characterize, the
physiological roles of P2XRs in non-excitable cells were
more difficult to visualize. Even if in situ hybridization
revealed staining for P2XRs on non-excitable cells, this was
met with some skepticism.
Emerging studies have revealed abundant expression of
P2XRs on non-excitable cells and tissues. Although sensory
organs do contain neurons that convey sensory inputs to
higher neural centers, evidence has emerged that P2XRs are
expressed in other more specialized, non-excitable cell types
in inner ear, retina, and taste bud. Multiple P2XRs have
been localized to spiral and vestibular ganglia of the inner
ear, the cochlear nucleus, and primary auditory neurons
[118–120]. In addition, P2X2 receptors or splice variants of
P2X2 [121] have been found biochemically, molecularly,
and functionally in Dieters’ cells of the cochlea [122], organ
of Corti within the cochlea [123], outer hair cells [119], and
epithelial cells lining the stria vascularis, Reissner’s mem-
brane, and the tectorial membrane [118]. P2X2 staining was
also intense in the hair cell stereocilia, indicating a key role
in sound transduction [124]. In the retina, P2XRs are also
abundant [125–130]. In addition to transduction of pain,
light, and sound, P2XRs have also been identified in
circumvallate fungiform papillae of the rat tongue [131].
The role of P2X1 in the smooth muscle cells of the testes
and vas deferens has already been well documented with
regard to cloning of P2X1 and the P2X1 knockout mouse.
The urinary bladder appears to be another important tissue
regulated by local ATP release and P2XRs. In detrusor,ureteral, and bladder blood vessel smooth muscle, P2X1
immunoreactivity was observed routinely and markedly on
the smooth muscle cell membrane [132]. While P2XR
expression remains and is pronounced in smooth muscle,
P2XR expression in skeletal muscle is notable during early
stages of development, while expression fades during the
postnatal period and in adult tissue [133,134]. Recently,
P2X4 was found in chick cardiac muscle myocytes. A
positive ionotropic effect of ATP on heart muscle may be
mediated by this P2XR subtype and allow ATP-induced
calcium influx that was blocked by antisense oligonucleo-
tides to P2X4 [135]. In addition, glycosylated (58 kDa) and
nonglycosylated (44 kDa) forms of the transfected cP2X4
receptor were found in cardiac myocyte membranes, a
similar phenotype to the epithelial P2X4 receptor (see
below). Only the 58 kDa glycosylated form of cP2X4 could
be biotinylated. These results provide a new tissue where
P2XR expression and function may be critical.
Very recent work has shown the presence of P2XRs in
human vascular endothelial cells [45,136–140]. In the
context of expression profiling in excitable tissues, hints
in these initial studies led to the characterization of P2XR
expression and/or function in epithelial cells in vitro and in
vivo [141]. An emerging role for purinergic receptors in the
cells that constitute skeletal bone is being appreciated. Bone
remodeling within microenvironments is regulated by auto-
crine and paracrine factors and by local mechanical forces
that are poorly understood. A recent and comprehensive
study on P2X and P2Y receptor expression in bone cells has
been performed [142]. Three studies that followed added
credence to these findings [143–145].
Burnstock et al. have led the field in documenting P2X
receptor expression in endocrine tissues. Initial work docu-
mented abundant P2X2 receptor expression in the nuclei and
neurons of the hypothalamus [146,147]. Similar work has
been performed in thyroid and adrenal gland [148–151].
Petit et al. showed roles for P2Y and P2X receptors in
stimulating insulin secretion from pancreatic h cells in the
absence or presence of the requisite extracellular glucose
stimulus [152]. Burnstock’s group has also studied expres-
sion of all P2XR subtypes in rat testis [153]. Taken together,
expression of multiple P2XR subtypes in endocrine organs
argues for tight, local control of endocrine tissue function by
autocrine purinergic signaling.
6.7. Biochemistry of P2XRs in native cells
Recent studies have shed new light on P2XR biochem-
istry in native cells and tissue. Most of this biochemical
work has been performed in heterologous cell systems with
transfected and, often, epitope-tagged P2XR constructs.
Recently, Hu et al. [135] made a step closer to studying
native cells by studying the protein biochemistry of a
transfected chick P2X4 receptor in cultured embryonic
ventricular myocytes. Not only did Hu et al. show compel-
ling evidence for a role for P2X4 in calcium influx from
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heart, they also showed the fact that P2X4 receptors were
resistant to various rather harsh detergents under various
biochemical conditions. Initially, they verified that the P2X4
receptor was found in two forms: a nonglycosylated 44 kDa
forms and a glycosylated 58 kDa form. Only the glycosy-
lated form was biotinylated and reacted with streptavidin,
suggesting that glycosylation was necessary for normal
trafficking. Interestingly, the glycosylated form was soluble
in all of the detergent combinations listed above.
Our laboratory has confirmed these results in human
epithelial and endothelial cell models for the human and
mouse P2X4 receptor [44,45]. The novel aspect of these
studies is the immunoblotting of native epithelial and
endothelial P2X4 receptor. Similar results have also been
obtained in non-CF and CF human airway epithelial cells
[154] and normal and PKD kidney epithelial cells (A.T.
Boyce and E.M. Schwiebert, unpublished observations).
Our laboratory has also seen higher molecular weight forms
in immunoblotting that are competed away by the peptide
immunogen, suggesting higher order glycosylation and/or a
detergent-resistant multimer. The prominent carbohydrate
addition on this large extracellular loop, elaborate disulfide
bonding between conserved cysteines (see below), and the
reaction with the extracellular domain of the ATP agonist as
well as heavy metals such as zinc, protons, and cations (see
below) suggests a complex and dynamic protein worth
further investigation in native cells as well as crystallogra-
phy of P2XRs.
As introduced above, the P2XR extracellular domain has
two cysteine-rich regions, within which each P2XR has 10
conserved cysteine residues in identical locations. This
argues for a complex, three-dimensional structure that begs
to be crystallized. ENaCs have 14 conserved cysteine
residues in their extracellular domains. Recent work sug-
gests that ENaCs have Kunitz-like domains that are suscep-
tible to protease cleavage, which is argued to be a major
mode of activation for these channels [155]. Further proof
for this is that protease inhibitors attenuate ENaC activity.
The effect of proteases on P2XRs has not been tested.
The role of the cysteines in forming intra- and interchain
disulfide bonds and creating trafficking-competent P2X1
receptor channels was addressed very recently by Ennion
and Evans [156]. A very important finding in this study was
the inability to label wild-type receptors with MTSEA-
biotin, suggesting that all 10 cysteine residues are engaged
in disulfide bonds. When most single cysteines were mu-
tated, only modest effects were observed on ATP potency at
the receptor channel. However, exceptions were C261A and
C270A, where the peak current amplitudes were reduced by
almost 100%. This, however, was determined to be an effect
on trafficking. The other single cysteine mutants did allow
MTSEA-biotin labeling, suggesting that companion cys-
teines were not free to react with the methanethiosulfonate
compound. Based on their work, they proposed the follow-
ing pairs of cysteines that were disulfide-linked: C117–C165, C126–C149, C132–C159 in the first cysteine-rich
region and C217–C227 and C261–C270 in the second
cysteine-rich region. Channel function is not affected sig-
nificantly by these bonds; however, trafficking is severely
disrupted by the elimination of the C261–C270 bond or by
the C117–C165 bond together with another bond.
6.8. Pharmacology and chemistry of P2XR receptor channel
activity
The extracellular domain of the P2X receptor channel is a
rich background for complex chemistry. As it accounts for
two-thirds of the molecular mass of the receptor channel
protein like its relatives in the ENaC/degenerin family, this
protein can be thought of more as a receptor than a channel.
In fact, its extracellular domain is so large and complex that
P2XRs can also be thought of as sensors rather than
receptors. Along this line of reasoning, ENaCs and degen-
erins may have endogenous chemical ligands that are not yet
appreciated.
This chemistry begins with the binding of its gating
ligand, ATP. Agonists and antagonists have been presented
in the context of work discussed above. However, recent
work has identified additional antagonists for P2XR sub-
types, including TNP-ATP [157,158], NF-279, a suramin
analog [159,160], and pyridoxal-5V-phosphate-6-(2V-naph-
thylazo-6V-nitro-4V,8V-disulfonate (PPNDS) [161]. Despite
these recent efforts, these antagonists mainly affect P2X1,
P2X2, and P2X3 or mixtures thereof. The lack of agonists
that are selective between P2Y and P2X receptor families,
and the lack of agonists and antagonists that define partic-
ular P2XR subtypes (in particular, P2X4, P2X5, and P2X6)
is a major roadblock in the P2 receptor field and in the
P2XR field that needs to be overcome.
Not only does the P2XR extracellular domain have sites
for agonist and antagonist binding, N-linked glycosylation,
cysteine bonding, and, possibly, protease cleavage, protons
and heavy metals react within this extracellular domain as
well. Stoop et al. [162] explored the sensitivity of four
P2XR subtypes to changes in extracellular pH (pHo). P2X3
homomultimers are only mildly inhibited by acidic pH (pHo
of 6.3 versus 7.3) and are unaffected by an alkaline pHo of
8.3. In contrast, P2X2 homomultimers and P2X2/P2X3
heteromultimers show profound stimulation by acidic pHo
and almost complete inhibition at alkaline pHo. The authors
noted that the data pointed to a single site being modulated
by protons. For P2X1 and P2X4, opposite effects were
observed with acidic versus alkaline pHo. Acidic pHo
profoundly inhibited P2X4 currents in particular, while
alkaline pHo had little effect. Site-directed mutagenesis of
the extracellular domain of the rat P2X2 receptor revealed
that acidic pH potentiated ATP stimulation more than 4-fold
in wild-type channels and eight mutant channels in which
extracellular histidines were mutated [163]. In P2X2, only
one histidine mutant, H319A, attenuated the effect of acidic
pH down to 1.4-fold. Substitution of a lysine instead of an
Fig. 6. Key residues within the generic P2XR. Most of the key residues highlighted in this cartoon have been defined in the P2X1 and P2X2 receptors. Not all
characteristics may hold for the other P2XR subtypes, especially with regard to H+ and Zn2 + modulation. Cation binding residues were found by multiple
laboratories throughout both a-helical regions.
E.M. Schwiebert, A. Zsembery / Biochimica et Biophysica Acta 1615 (2003) 7–32 21alanine reduced the EC50 for ATP 40-fold. Extracellular
Zn2 + is known to potentiate and inhibit the responses of
different P2XR subtypes to ATP. The maximal effective
dose is only 20 AM, which falls within physiological limits
for this trace element. Zn2 + potentiates ATP gating of P2X2,
P2X3, P2X4, P2X2/P2X3, P2X2/P2X6, and P2X4/P2X6,
while it inhibits ATP’s effect on P2X1 and P2X7. ZnCl2
potentiated the response to ATP in wild-type P2X2 and
seven histidine mutants by 8-fold; however, in two mutants,
H120A and H213A, Zn2 + had no effect [163]. Because
these two Zn2 + reactive histidine residues are rather distant
from one another within the external domain, two different
sites may be required for the effect of Zn2 + or the two
histidines may interact with each other in a three-dimen-
sional model of the extracellular loop. Taken together, these
results suggest that multiple but different histidine residues,
whose pKa falls within the range tested in these studies, bind
protons and heavy metals to modulate the gating by the
physiologic agonist, ATP. The opposite effects of pH and
Zn2 + on P2X2 versus P2X4 is borne out by less total
histidines in P2X4 and locations of these cysteines that are
completely different than in P2X2. It is also possible that H
+
and Zn2 + could act as agonists independent of ATP to open
P2XRs. Fig. 6 highlights the histidine residues implicated in
H+ and Zn2 + binding.7. Physiological and pathophysiological paradigms for
extracellular ATP-mediated effects in epithelia
Many of the figures included above were designed in the
context of a polarized epithelium. This was no accident.Autocrine and paracrine ATP signaling in extracellular
microenvironments is robust on both the apical and baso-
lateral sides of polarized epithelium. Epithelial cells are
traditionally known as barrier cells that line the tissues of
many organs of the body and separate the external environ-
ment from the interstitium. The apical membrane faces the
lumen of a tissue. Often, this is the external environment,
like the humidified air in the lung or a fluid-filled environ-
ment (e.g., the humor-filled eye, the ventricles of the brain
filled with cerebrospinal fluid (CSF), or the endolymph-
filled inner ear). The basolateral membrane faces the inter-
stitium (e.g., basal cells, connective tissue, basement mem-
brane, blood supply, and nerve innervation). The
microenvironments on the surfaces of these two membrane
domains are very different. These microenvironments often
provide an ideal setting for autocrine and paracrine puriner-
gic signaling in particular and autocrine and paracrine
signaling in general. This is especially true if they are
fluid-filled or fluid-covered microenvironments that have a
medium to allow the autocrine or paracrine mediator to
diffuse easily and rapidly.
Purinergic signaling has been implicated in the regula-
tion of many epithelial cell functions. In addition to
triggering cell signaling, mainly through cytosolic calcium
and phospholipase-coupled signal transduction and, possi-
bly, via other cellular mechanisms, extracellular nucleotide
signaling also modulates the potency of other autacoids and
hormones that regulate epithelial cell function. Extracellular
nucleotides and nucleosides also regulate transepithelial ion
transport. In general, extracellular nucleotides and nucleo-
sides, through P2Y, P2X, and P1 receptors, stimulate
secretory Cl and H2O transport, activate K
+ channels,
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port, and potentiate regulatory volume decrease following
hypotonic cell swelling. We are careful to say ‘‘in general,’’
because there are exceptions to this rule due, in large part,
to where the epithelium resides and its function. For
example, in highly secretory epithelium like choroid plexus
or ciliary processes of the ciliary body of the eye, purinergic
signaling may also stimulate secretory Na+ transport. Puri-
nergic receptor-driven functions include triggering of calci-
um sparks and waves, potentiating ciliary beat frequency,
and promoting mucus, glandular, and acinar secretion.
Constitutive ATP release and signaling has been implicated
in the maintenance of cell signaling ‘‘setpoints’’ for cyto-
solic calcium, phosphoinositide turnover, and arachidonic
acid metabolism. Purinergic signaling may even modulate
gene expression in epithelial cells via specific transcription
factors.
In epithelial cells, ATP is released from the cell in a
polarized manner either at the apical or basolateral cell
surfaces for the purpose of autocrine and paracrine regula-
tion of the epithelial cell monolayer. In general, ATP release
is directed apically. However, there may be physiological
and pathophysiological exceptions to this rule as well
(macula densa of the kidney as an example, see below).
The mixture of P2Y, P2X, and P1 receptors in the apical and
basolateral membrane domains may also differ. Neverthe-
less, a given epithelial cell commonly expresses all three
purinergic receptor subfamilies and, often, multiple P2Y,
P2X, and P1 receptor subtypes (see also below). That
mixture of purinergic receptor subtypes governs what nature
of signal is transduced from the released ATP and its
metabolites, either in the luminal (apical) or interstitial
(basolateral) microenvironments.
7.1. Lung and airway epithelium
There are two general sites of ATP release and signaling
in the human lung and airways: the airway lumen and the
submucosal gland secretions (Fig. 7). Although it has not
been investigated to date, ATP secretion in the distal lung at
the gas exchange zone may also occur with surfactant
secretion. Airway surface epithelium in the smaller and
larger conducting airways is capable of ATP and UTP
release [164] in response to a myriad of stimuli (flow, touch,
cyclic nucleotides, hypotonicity, and calcium agonists);
moreover, secretions from submucosal glands that lie be-
neath the pseudostratified surface epithelium may also
supply autocrine nucleotides and nucleosides. Neuroendo-
crine cells, mast cells, and goblet cells along the airway may
also release ATP along with other agonists from their
granules. The analogy of the submucosal gland secreting
purinergic agonists with mucins and other substances can be
extended to the hepatic and pancreatic acini and the secre-
tory glands/coils of the sweat gland and the salivary gland.
With regard to microenvironments, however, the airway
surface liquid (ASL) bathing the cilia on ciliated airwaysepithelium in the large conducting airways is a microenvi-
ronment of interest in physiological paradigms and in
pathophysiological contexts such as cystic fibrosis (CF)
and primary ciliary dyskinesia (PCD) [165,166]. Because
purinergic signaling governs ciliary beat, epithelial cell
signaling, and epithelial solute and water transport, extra-
cellular nucleotide and nucleoside signaling in this micro-
environment may be essential to regulating the composition
of the ASL and the function of this critical extracellular
space. Several laboratories, including our own, have found a
loss of purinergic signaling in CF epithelial and heterolo-
gous cell models lacking CFTR [17]; as such, loss of
purinergic signaling may be critical to the loss of CFTR
function, loss of ciliary beat, abnormal ASL composition,
and overall loss of mucociliary clearance. These issues will
be revisited below.
As agonists were being screened to restore chloride and
fluid secretion in CF airways epithelium, nucleotide ago-
nists emerged quickly as chloride and fluid secretagogues
that stimulated chloride and fluid secretion independent of
CFTR. Importantly, Knowles et al. [167] showed that
extracellular nucleotides stimulated chloride secretion in
human patients with CF, triggering interest in targeting any
and all purinergic receptors for CF therapy. Importantly,
purinergic agonists in addition to ATP such as UTP, UDP,
and ADP (as well as poorly hydrolyzable analogs of those
listed) were also efficacious in CF as well as non-CF
airway epithelial model systems [168,169]. This led to
the identification of P2Y1, P2Y2, P2Y4, and P2Y6 recep-
tors in human airway epithelial model systems [170]. In
addition, adenosine receptors (the P1 receptors) also stim-
ulated chloride secretion in airway epithelial cells [171];
however, the major adenosine receptor, the A2 receptor,
activates the cAMP/PKA signal transduction cascade and,
eventually, CFTR. It is dysfunctional in CF. Several other
laboratories have confirmed as well as extended these early
findings in human epithelial cells or cells from other
species [172–175].
Our laboratory has added work showing abundant ex-
pression and function of the P2X purinergic receptor chan-
nels in epithelia [141]. Biochemical characterization of
P2X4 and P2X5 in human airway epithelial model systems
with subtype-specific antibodies is currently in progress in
our laboratory. We also cannot rule out the possible expres-
sion of P2X6, which is not detected by our degenerate RT-
PCR primers and for which antibodies are not available. A
unifying theme in this chapter will be the fact that most, if
not all, epithelial cell models express both P2Y G protein-
coupled receptors and P2X receptor channels, sometimes in
the same membrane domain of the polarized epithelium
(Fig. 7). Because each class of receptor increases cytosolic
calcium, albeit via different mechanisms, both receptor
subtypes are viable targets for pharmacotherapy of CF in
the lung and airways (see below).
Both P2Y G protein-coupled receptors, via phospholi-
pase-induced release of Ca2 + from intracellular stores, and
Fig. 7. Nucleotide signaling in the airways epithelium. Schematics of the whole lung and airways, a cross-section of a large airway with the many different
subtypes on the surface and a submucosal gland beneath, a multi-ciliated airways epithelium segment of a large airway, and a single airway epithelial cell
showing just some of the many functions that autocrine an paracrine purinergic signaling modulates. This regulation breaks down in CF (see text for details).
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channel from extracellular stores are capable of triggering
calcium-dependent signal transduction cascades. P2Y-medi-
ated effects on Ca2 +i have been studied extensively in
human airway epithelial cell models by Paradiso and others
[176]. Zsembery et al. [154], using an IB3-1 CF human
airway epithelial cell model for therapeutic implications in
CF airway, have shown that both P2Y and P2X subtypes
increase cytosolic calcium. Intriguingly, ATP stimulates
both subtypes, although a fully transient increase in calcium
is triggered by P2Y receptors, while P2X receptors cause asustained increase in Ca2 +i (perhaps through the P2XR
channels themselves and/or by opening store-operated or
‘‘Transient Receptor Polarization (TRP)’’ calcium chan-
nels). P2X receptor channel-mediated increases in cytosolic
calcium are greatly potentiated by removal of extracellular
Na+ by replacement with NMDG [154]. We interpret this
result to suggest that Na+ competes with Ca2 + as each cation
passes through the ATP-gated pore (each cation has a
favorable gradient for entry). The P2X receptor-induced
calcium influx is prevented by EGTA and augmented by
raising extracellular Ca2 + [154].
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pronounced, additive, and sustained increase in Ca2 +i. This
fact is critical for several reasons. First, either or both
receptors could be targeted to trigger calcium-induced
chloride secretion and potassium channel opening, which
would be beneficial to the CF epithelium. Second, both
receptors could be targeted to suppress absorptive Na+
channels by calcium-dependent mechanisms. Such effects
on all of the above would also correct abnormal cell volume
regulation in the CF airways epithelium (see below). Local
increases in calcium also augment ciliary beat frequency
(see below), which would benefit attenuated mucociliary
clearance in CF. Targeting either or both ATP receptor
subfamilies for pharmacological therapy of the CF lung
and airways is logical and feasible and takes full advantage
of naturally expressed membrane proteins that are largely
apical but are also basolateral.
Early work from Knowles et al. [167,171] showed that
purinergic agonists stimulated chloride secretion in CF as
well as non-CF airway epithelial model systems. The most
important demonstration of this was in in vivo nasal
potential difference (PD) measurements in CF patients
[167]. Jiang et al. [177] subsequently showed that purinergic
agonists stimulated fluid secretion in CF and non-CF airway
epithelial cells. Purinergic agonists emerged from a ‘‘kitchen
sink’’ approach of adding a large panel of agonists to CF
epithelial model systems to identify which agonist, if any,
could stimulate chloride secretion independent of CFTR.
Many studies confirmed this work in other airway epithelial
model systems from human and other species. Guggino et
al. showed that purinergic receptors stimulated multiple
types of chloride channels, including CFTR and the ORCCs
from both the apical and basolateral membranes of primary
rat tracheal epithelial cell monolayers [169]. It was con-
cluded that the P2Y2 receptor was critical to the apical-
mediated stimulation of chloride secretion; however, rank
order potency pharmacology most consistent with the P2Y3
receptor (a species homolog to P2Y1) stimulated chloride
secretion from the basolateral side. As mentioned, UDP and
ADP also stimulated chloride secretion in airway epithelia.
Epithelial cells release ATP in response to hypotonicity
or dilution of the extracellular osmolality [17,19,21,47,
51,178]. Hypotonicity-induced ATP release is potentiated
by the expression of CFTR in the epithelial cell and is
dampened when CFTR is absent from the plasma membrane
[17,19]. Because CFTR is a regulator of other ion channels,
transporters, and vesicle trafficking and fusion, CFTR may
augment ATP release by positively regulating any and all of
these ATP release mechanisms [17].
More recently, our laboratory has shown that CF human
airway epithelial cells are sluggish in their recovery from a
hypotonic insult, a process known as regulatory volume
decrease or RVD [17]. Transient or stable transfection of the
wild-type CFTR cDNA into CF human airway epithelial
cells corrects defective cell volume recovery in response to
hypotonicity. Wild-type CFTR modulation of human airwayepithelial cell volume regulation is blocked by the ATP
scavengers, hexokinase or apyrase, and the global P2
receptor antagonist, suramin. Taken together, these data
suggest that the presence of CFTR in the plasma membrane
and CFTR-dependent ATP release govern epithelial cell
RVD. This result begged the question: would addition of
selective purinergic agonists to P2Y and P2X receptor
subtypes rescue defective volume regulation in CF human
airway epithelial cells. This is indeed the case. Both P2X
receptors and P2Y receptors stimulate chloride and, likely,
potassium efflux from epithelial cell during RVD. This is
one critical answer to the question: why would a particular
epithelial cell model express both P2Y and P2X receptors in
the same cell? One answer is for protective redundancy
against osmotic or other environmental insults (anoxia and
ischemia, for example). Because epithelial cells are exposed
to very different and dynamic microenvironments on their
apical and basolateral sides, epithelial cells may express
P2Y and P2X receptors in both membrane domains for this
protective redundancy. A similar paradigm is evolving in
hepatocytes and cholangiocytes in work by Feranchak et al.
[47,178]. Another answer is simply that P2X receptors
mediate fast and sustained increases in calcium signaling,
while P2Y receptors mediate slower and only transient
increases in cytosolic calcium.
In addition to stimulating Cl and K+ efflux from the
epithelial cell, ATP (and UTP) have also been observed to
inhibit Na+ influx pathways. Devor and Pilewski [179] have
shown that UTP, by binding to purinergic receptors and
increasing intracellular calcium concentrations, leads to a
long-term inhibition of Na+ entry to the cell from the apical
media. This was studied in cells with normal and mutant
forms of CFTR. They conclude that nucleotides (ATP and/
or UTP) could have a dual therapeutic role in the airway,
stimulating Cl efflux and inhibiting Na+ entry. This con-
clusion has been borne out by a handful of studies in airway
and other miscellaneous epithelial cell models, showing that
stimulation of purinergic receptors stimulates Cl secretion
while, at the same time, attenuating Na+ absorption. Inglis et
al. [180] studied these effects in distal bronchi and in rat
fetal distal lung epithelial cells [181]. Iwase et al. [182]
showed similar results in rabbit tracheal epithelium. While
these were different preparation of distal airway epithelial
cells, the conclusions were similar. ATP and UTP evoked a
transient stimulation of Cl secretion and a sustained
inhibition of Na+ absorption in the polarized monolayers
of distal airway epithelia. In the nasal PD measurements of
porcine distal bronchi, transepithelial PD was measured in
cannulated and perfused preparations. UTP hyperpolarized
the PD transiently; this stimulation was inhibited by serosal
bumetanide. PD then declined to a sustained level lower
than basal; this sustained inhibition was prevented by
luminal amiloride. Because thapsigargin failed to inhibit
UTP-stimulated Cl secretion but did block the inhibition of
Na+ absorption, these results suggest that UTP stimulates
Cl secretion by a calcium-independent mechanism, while
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et al. argue that both effects of extracellular nucleotides
should promote hydration of the airway.
The mucociliary system in the airway is necessary for
optimal removal of mucus and inhaled pathogens and
particles. Cilia on the surface of the airways epithelium
beat at regular intervals and in a uniform direction toward
the pharynx, and this facilitates the movement of materials
along and up the ‘‘mucociliary escalator.’’ A key stimulus
for enhancing ciliary beat is increased intracellular Ca2 +
concentrations within the cilia themselves. If Ca2 + influx is
impaired, this could lead to jeopardized mucociliary clear-
ance and disease. Of the hormones and neurotransmitters
that are known to stimulate ciliary beat, the most potent is
ATP. ATP acts primarily in this system by stimulating Ca2 +
influx from the external milieu, as well as stimulating
internal stores to release Ca2 +. Ma et al. [183] have shown
that extracellular sodium ions actually inhibit an ATP-gated
calcium channel, perhaps through competition of both
cations for the ATP-gated pore. Na+, therefore, attenuates
ATP-dependent ciliary beat. Their findings suggest a phys-
iologically significant relationship between Na+ concentra-
tions and ciliary beat. This has potentially significant
therapeutic implications, suggesting that decreasing airway
surface fluid Na+, while increasing Ca2 + in this fluid, may
augment calcium influx into the cilium via P2X receptors
and could increase mucociliary clearance in such diseases as
cystic fibrosis, primary ciliary dyskinesia, or chronic bron-
chitis (Fig. 7).
7.2. Cystic fibrosis: a loss of extracellular purinergic
signaling in the lung airways and in other tissues
Our laboratory as well as other laboratories have docu-
mented a role for CFTR and other ABC transporters in
governing ATP release and autocrine and paracrine puriner-
gic signaling. In the disease, cystic fibrosis (CF), purinergic
signaling is attenuated. We believe that this defect, along
with the primary defect in Cl channel function and Cl
permeability [184], are major contributing factors to the
abnormalities in the CF airway and, possibly, in other
tissues affected in CF.
The CFTR protein is widely believed to form an anion
channel in the apical membrane, but there is speculation as
to exactly what it transports. There is a large amount of
evidence that CFTR is a Cl channel activated by cAMP.
Some believe that CFTR also has the capacity to conduct
ATP [11], but this is very controversial [13]. Past and
current research is focusing on a separate ATP conductance
channel that is closely associated with the CFTR protein
[17,18]. Because CFTR also regulates numerous other
processes in the airway epithelial cell, CFTR may regulate
ATP release, mediated by ATP channels and ATP-filled
vesicles, to accomplish these other regulatory functions.
It has been shown that CFTR is necessary for extracel-
lular nucleotide signaling. In CF epithelial cells that lackfunctional CFTR at the apical membrane, nucleotide sig-
naling is absent or insufficient. Therefore, the physiological
consequences of this lost signal must be addressed. There is
a loss of chloride conductance that may be necessary for the
chloride secretion involved in RVD and transepithelial
transport [12,167]. There could also be a loss of potassium
and fluid secretion due to the loss of nucleotide signaling,
two processes also critical in RVD. These consequences
could lead to impaired intracellular cell volume regulation.
An impairment in intracellular volume control, due to an
inability of the epithelial cell to ‘‘sense’’ its external osmotic
environment and/or to regulate its own volume, may also
directly impact upon the abnormal ASL microenvironment
observed in CF. Smith et al. [185] have observed a curious
increase in ASL ionic strength in CF epithelia when
compared to non-CF cells. This would also increase the
tonicity of this microenvironment. Matsui et al. [186]
observed a reduced ASL depth and volume in CF epithelia,
but no difference in ionic strength. Zhang and Engelhardt
[187], using their elegant xenograft model of well-differen-
tiated non-CF and CF epithelia, showed defects in ionic
strength and volume in the CF ASL versus the normal
counterpart. These results and hypotheses relate back to
an older and unappreciated study by Valverde et al. [188],
who observed defective cell volume regulation in the
intestinal crypts of CF knockout mice when compared to
wild-type mice. The possibility that these defects in ASL
composition and cell volume regulation may be caused by
defects in autocrine ATP release and signaling remains to be
determined.8. Epithelial cells along the renal nephron
Once filtered at the glomerulus or secreted into the lumen
of the nephron (proximal tubule cells release micromolar
quantities of ATP) [21,44,189], the ATP is trapped in the
tubular lumen as a signaling molecule. It is then propelled
downstream by the tubular fluid rapidly and robustly where
it can act on downstream tubules in a paracrine manner.
Cells derived from multiple nephron segments express
multiple P2Y, P2X, and P1 receptors, and Leipziger et al.
and Satlin et al. [190–192] have shown the presence of
luminal P2 receptors in isolated and perfused cortical
collecting tubule or duct (CCT or CCD) preparations from
mouse and rabbit. Even once that ATP is excreted in the
final urine and exits the nephron, it can signal the uroepi-
thelium (or urothelium) in the ureter and urinary bladder.
Moreover, the urothelium releases ATP in response to
increased distension of the ureter, the bladder, and associ-
ated structures [193]. Taken together, the lumen of the
nephron and beyond provide an ideal microenvironment
with a fluid medium that can transmit this autocrine and
paracrine signaling molecule (Fig. 8).
The process of tubuloglomerular (TG) feedback, where
changes in the luminal content of salt and water is sensed by
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and where that sensation is transduced to the glomerulus of
the same nephron, is widely accepted but poorly understood.
A long-held hypothesis is that a local mediator or paracrine
agonist may be released by MD cells and regulate vascular
tone of the glomerulus by causing contraction of glomerular
mesangial cells and constriction of the afferent arteriole of
that glomerulus. Past work has suggested that adenosine may
be that mediator. Through an elegant, freshly dissected
cTAL/MD/glomerular preparation, Liu et al. [30] are exam-
ining TG feedback signaling mechanisms more directly.
Briefly, they have found that changes in perfused NaCl
concentrations are sensed in the lumen of the cTAL by the
specialized MD cells, leading to ATP release from the
basolateral surface of the MD plaque. ATP or its metabolites
(adenosine, in particular) would then bind to glomerular
mesangial cells in the interstitium and, ultimately, vascular
smooth muscle cells in the afferent arteriole of the glomer-
ulus. Via P2Y and/or P2X receptor channels, ATP would
elevate cytosolic Ca2 + in both cell types, leading to con-
striction of the afferent arteriole and a decrease in renal blood
flow and glomerular filtration rate to that single glomerulus.
Adenosine could do the same via its A1 receptor. In short, it
is classic paradigm for paracrine purinergic signaling in-
volving specialized renal epithelial cells and their ‘‘cross-
talk’’ with other renal glomerular cell types.
8.1. Collecting duct
McCoy et al. [194] studied a mouse IMCD cell line
(mIMCD-K2) to determine if nucleotides regulated NaClFig. 8. Collecting duct epithelium in the context of the nephron. Schematic of th
collecting duct cell. Despite some similar modulation of NaCl and water transp
membrane on renal epithelia.transport and, if so, which purinergic receptor subtypes were
involved. They observed that ATP, ah-methylene ATP and
UTP stimulated Cl secretion and inhibited Na+ absorption.
These P2 agonists as well as specific and degenerate RT-
PCR implicated four receptor subtypes: P2X3, P2X4, P2Y1,
and P2Y2. Further analysis showed that apical nucleotide
receptors were more effective in inhibiting Na+ absorption
and stimulating Cl secretion. Leipziger et al. have found
similar results in M1-CCD cells and MDCK cells, and
Deetjen and Leipziger and, later, Satlin et al. [190–
192,195,196] found an apical P2Y2 receptor in isolated,
perfused CCDs that increases cytosolic Ca2 + in these
tubules. Similar modulation of ion transport in this segment
is likely. Purinergic receptors also modulate water transport
in the collecting duct. Kishore and Knepper found that
P2Y2 receptors were expressed along the nephron in general
and in renal medulla in particular. ATP and UTP, via this
receptor, inhibited vasopressin-induced water permeability
across the renal collecting duct. This paradigm is described
in detail in a recent review [56]. Fig. 8 shows a collecting
duct epithelial cell model illustrating this purinergic regula-
tion in this nephron segment.
8.2. Autosomal dominant polycystic kidney disease: a
change in nephron structure creates a detrimental autocrine
signaling environment
Purinergic receptors and signaling are also critical along
the nephron of the kidney. The richest source of ATP release
in the nephron is the proximal tubule. There are many
reasons why this is the case, including an acceleratede whole nephron and a cartoon of nucleotide regulation of a mono-ciliated
ort, P2XRs have only been show functionally to be present on the apical
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the expression of multiple ABC transporters like CFTR,
mdr, and MOAT. Once released into the tubular lumen, ATP
would be trapped as a charged anionic species and carried in
the tubular fluid downstream to the other nephron segments,
where it can bind to and interact with purinergic receptors.
Autocrine and paracrine ATP signaling in the tubular fluid
via purinergic receptors can affect any number of renal
functions, due to the versatility of purinergic control over
epithelial functions and signaling pathways (see recent
reviews, Refs. [56,189]).
Because purinergic signaling plays an autocrine and
paracrine role in the regulation of renal tubular function,
defects in purinergic signaling could contribute significantly
to kidney pathophysiology. Extracellular purinergic signal-
ing is known to modulate water and salt balance along the
nephron. Extracellular ATP in the apical environment or
tubular lumen has been shown to inhibit water and salt
reabsorption by the kidney. Therefore, the addition of
purinergic agonists has been proposed to be of therapeutic
benefit to decrease water and salt reabsorption, thus de-
creasing blood volume and pressure. A recent review
examined this paradigm in some detail [56].
The relationship between autocrine and paracrine puri-
nergic signaling and the renal disorder, PKD, is not intui-
tively obvious. However, PKD is a progressive disorder
characterized mainly from the slow and gradual remodeling
of the tubules of the kidney and the ducts of the pancreas
and liver. In autosomal dominant PKD (ADPKD), this
remodeling results in the formation of a fluid-filled cyst,
created from the closure of two ends of a renal tubule. In
autosomal recessive PKD (ARPKD), the tubules and ducts
dilate; however, they only form cyst-like structures in end-
stage disease that never fully close off. Either way, an
abnormal microenvironment encapsulated by a single
monolayer of epithelial cells develops. As alluded to above
and in other reviews, such a microenvironment is ideal for
autocrine and paracrine signaling [197].
Our laboratory has shown that ATP (and, likely, its
metabolites) are present in micromolar quantities in a subset
of ADPKD cyst fluid samples [21]. In this study and in
another very recent one [44], ATP release was found to be as
or more robust in PKD epithelia versus normal controls.
This could be due to increased metabolism and/or prolifer-
ation of PKD epithelia during their reversion to an undif-
ferentiated phenotype. More recent work has shown that
both P2Y and P2X receptors are present on the luminal
membrane of human ADPKD monolayers that stimulate
Cl secretion by a cytosolic calcium-driven mechanism. As
such, all of the elements are present for autocrine and
paracrine ATP and ATP metabolite signaling to drive Cl
secretion into the cyst. Obviously, this would be detrimental
to the progression of ADPKD. An additional problematic
feature of ‘‘trapped’’ purinergic signaling within the cyst is
the fact that purinergic agonists are mitogens or co-mitogens
along with growth factors for renal epithelial cells andmesangial cells [198–200]. In PKD, growth factors are also
released instead into the cyst. There, they interact with
growth factor receptors mislocalized to the luminal mem-
brane, leading to a devastating positive feedback loop for
growth and proliferation of the cysts [201,202]. The auto-
somal dominant form of PKD (ADPKD) results in distinct
cysts, or fluid-filled spheres lined by epithelial cells. Any
normally apical ion or fluid transport is instead released into
the encapsulated cyst. Therefore, any secretagogue could
prove to be detrimental. Growth factors are normally re-
leased apically from the cell. Therefore, in some cell
models, purinergic agonists were observed as mitogens or
co-mitogens with growth factors. Therefore, ATP release
into the cyst lumen could further prove to be detrimental.9. Hair cell epithelium of the inner ear
The hair cells that line the cochlea of the inner ear
respond to sound waves that enter the ear. ATP has been
shown to be present in the endolymph, the fluid medium of
the inner ear that bathes the hair cells [203]. Moreover, P2X
purinergic receptor channels are present on the stereocilia
that lie atop each hair cell [204]; the cilia bend in response
to each sound wave and the mechanical changes in the cilia
are transduced from a mechanical signal to an electrical one.
Purinergic signaling is emerging as a critical process in
sound transduction by the cilia on the hair cell [203]. Not
only could ATP be released from the hair cells but that ATP
could bind to the P2X receptors on the cilia to augment
ciliary beat.
ATP is a critical autocrine and paracrine agonist in the
endolymph and the scala media that fill the organs of the
inner ear. P2 receptors have been found throughout the
specialized epithelial cells and cell membranes that are
present in the cochlear and vestibular system. This topic
has been reviewed recently by Housley [203]. Basal levels
of ATP in the perilymph and endolymph are nanomolar, and
they increase in response to noise stress, sound waves, and
hypoxia. Ecto-ATPases and ecto-apyrases may suppress the
levels of extracellular ATP; however, the full range of
stimuli for ATP release may not be appreciated and
increases in ATP release (surrounding the stereocilia of the
hair cells, for example) may not be readily detectable.
Housley cites that the sources of released ATP are not
appreciated and present an important future direction of this
work. However, a recent study by Munoz et al. [205]
showed that stores of ATP located in vesicles within
marginal cells of the stria vascularis were released to
increase ATP in the endolymph significantly following a
sound stimulus. In contrast, hypoxia did not promote a
statistically significant increase in endolymph ATP, although
a slight increase was noted. It was also noted that substantial
ATP was present under basal conditions, suggesting a role in
the maintenance of inner ear and cochlear and vestibular
function.
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it is known that extracellular ATP modulates transduction of
sound waves by action of P2X receptors on the stereocilia
and by P2Y receptors there and elsewhere. This is reviewed
elegantly by Housley [203]. It is thought that P2X2 recep-
tors function together with stretch-activated non-selective
cation channels in the stereocilia to depolarize the outer hair
cell membrane, suggesting that ATP may play a significant
role in the inner ear signaling transduction pathway
[124,206,207]. However, it is possible that additional P2X
receptor subtypes may contribute to the phenotype in
particular inner ear cell types. P2X receptors also play
critical roles in Reissner’s membrane and in intermediate
cells of the stria vascularis, where they mediate K+ shunt
conductances [208]. It could be argued that the P2X receptor
channels and other secretory K+ channels contribute to the
high K+ concentrations in perilymph and endolymph. In-
deed, mutation of the KvLQT channel in the stria vascularis
marginal cell causes deafness in patients that also have long
QT syndrome of the cardiac myocyte. The P2Y4 and P2Y2
receptors also play a critical role in regulating this KvLQT
and other KCNE channels in strial marginal cells and
vestibular dark cells [209,210]. Deeper in the inner ear,
Marcus et al. have also found a role for P2X2 receptors in
parasensory cation absorption by cochlear outer sulcus cells
and vestibular transitional cells [204]. In fact, guinea pigs
with vestibular imbalance disorder were corrected by infu-
sion of ATP and other purinergic agonists into the scala
tympani.
Purinergic signaling also affects other inner ear epithelial
cell functions. Hensen’s cells of the cochlea, specialized
epithelial cells in the inner ear, respond to extracellular ATP
with changes in ionic currents and concomitant increases in
Ca2 +i [211]. Ionic currents that were activated included a
rapid inward current, a more slowly rising inward current,
and a slowly developing reduction in input conductance.
ATP also appeared to inhibit cell–cell communication via
gap junctions. The fast current activated by ATP were the
P2X receptor channels located on these and other special-
ized sensory epithelial cells in the cochlea, while P2Y
receptors mediated the slow responses in ionic currents
and Ca2 +i. The same group also performed similar work
on Dieter’s cells and showed that ATP promoted gap
junctional communication between cells. Unfortunately,
Fura-2 imaging of multiple cells within the tissue for
Hensen’s cells or Dieter’s cells was not performed to
monitor Ca2 + wave propagation. The inner ear and its
specialized epithelial cells designed to sense and capture
sound is a rich ground to study autocrine and paracrine
nucleotide signaling. Taken together, there are profound
physiological roles for extracellular ATP signaling and both
P2X and P2Y receptors in the specialized ciliated and non-
ciliated epithelial cells of the inner ear. Luciferase-based or
other detection methods need to be applied to freshly
dissected, endolymph-filled inner ear preparations to gauge
the role of extracellular ATP in an in vivo-like preparation.10. Future directions in the context of unanswered
questions
10.1. Why does a specific cell need P2Y and P2X receptors?
There are answers to this question already; however,
there will likely be many more. P2X receptors that allow
calcium influx directly are thought to be the fast-acting
purinergic receptor, while P2Y receptor mediate slower
responses. Having said that, both increase cytosolic calcium
within seconds; however, P2X receptors mediate sustained
calcium increases in epithelial cells. Thus, a cell may indeed
need both, and there is considerable evidence that neurons
and epithelial cells express both subfamilies. Our laboratory
has shown that both P2Y and P2X receptors are expressed
functionally in the apical membrane of airway and kidney
epithelia and vascular endothelia in vitro and in vivo
[45,46,142,195]. Another reason may be for redundancy
to protect against osmotic insult, anoxia or hypoxia, or other
forms of cell injury. Or, related to the next question, a cell
may need both for basal maintenance of essential functions
and cell signaling. Nevertheless, study of the native P2X
and P2Y receptors in these and other cells is becoming a
necessity.
10.2. Does ATP release and signaling within microenviron-
ments govern basal cell function and signaling?
Evidence is emerging that constitutive ATP release
occurs under basal conditions to maintain physiological
‘‘setpoints’’ for signaling and function. Ostrom et al. [212]
showed in Madin–Darby canine kidney (MDCK) cells that
phosphatidylinositol turnover and arachidonic acid metabo-
lism were altered when autocrine purinergic signaling was
abolished. Our laboratory has published evidence that basal
cytosolic calcium is modulated by endogenous ATP release
and signaling in epithelial cells [46]. We also have prelim-
inary evidence that endogenous ATP release and signaling
modulates cell volume regulation under isotonic conditions
and ciliary beat in airway and other preparations. Indeed, in
past cardiovascular paradigms, ATP and adenosine have
been characterized definitively as local metabolites that
modulate vascular tone. Again, these studies can only be
done in native cells and confirmed with heterologous cell
systems that are carefully handled.
10.3. Is signaling emanating from P2R activation only
dependent on calcium?
The answer to this question is likely to be complex.
Sustained increases in cytosolic free calcium derived from
P2XRs and extracellular stores may trigger calcium-depen-
dent protein kinases (CaCMKs, Pyk2, ERKs, PKC, etc.)
which may have many additional targets within the cell and
affect cell function in limitless ways. Some or all of these
calcium-dependent protein kinases affect the activity of
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accumulating more slowly that P2YRs may couple to other
signaling effector enzymes besides phospholipase Ch, in-
cluding PLA2 and PLD. Native cells will likely aid this
work and make it more physiologically relevant. Moreover,
care must be taken to rule out or account for endogenous
ATP release and signaling from the cell model or tissue
preparation itself that may influence signaling cascades
independent of exogenously applied agonists.
10.4. What is the stoichiometry of a P2XR multimer?
This is a ticklish question that is difficult to define or
characterize. There is controversy over this question in the
ENaC field as well as in every other ion channel field.
Because IRK channels likely form tetramers, it is assumed
that ENaCs and P2XRs may do the same. However, the
large extracellular domain that these subfamilies share and
is lacking in the IRK family may confound this multimeric
assembly. There is no doubt that multimerization is critical
for function; however, a consensus on stoichiometry would
help understand P2XR expression and function better.
10.5. Are P2XRs targets for therapy of different diseases?
Exogenous ATP has been shown to correct hearing dis-
orders. As such, it is possible that targeting of P2X2 on
stereocilia may be worth pursuing. P2XRs are a rich and
important target for therapy of CF. In airway epithelia,
multiple P2XR subtypes are expressed on both apical and
basolateral membrane domains. In vivo nasal PD measure-
ments showed a stimulation of chloride transport in CF
knockout mice as well as normal mice when the agonists
were added luminally. Current work has returned to this and
other assays with different conditions designed to maximize
P2XR activity and the sustained calcium increase that is
mediated by P2XRs. More importantly, the P2XRs expressed
in epithelia desensitize poorly (P2X2, P2X4, P2X5, and,
possibly, P2X6); the same cannot be said for G protein-
coupled receptors like P2Y2 targeted by other groups for CF
therapy. P2XRs, like P2Y2, would restore chloride and fluid
secretion and dampen sodium absorption but without desen-
sitization and with a sustained increase in cytosolic calcium.
This would correct abnormal cell volume regulation. Possi-
bly, the most important effect would be to amplify ciliary
beat frequency. Application of P2XR agonists would also
require modified conditions of the saline in which it was
nebulized and aerosolized to maximize its effect. Our labo-
ratory is ardently pursuing this therapeutic approach.
On the other hand, inhibition of P2XRs and, possibly,
other calcium entry channels may be beneficial for therapy
of ADPKD. This could suppress chloride and fluid secretion
and fluid accumulation as well as the enhanced proliferation
rate of the monolayers of renal epithelial cells that encap-
sulates the cyst, two hallmarks that enhance the progression
of the disease after cyst formation. At the same time,inhibition of calcium entry might augment ENaC-mediated
sodium and fluid absorption, causing the cysts to shrink.
Our laboratory is pursuing this therapeutic hypothesis.
These questions are just a few of the many that drive
those of us who are obsessed ‘‘purinergics.’’Acknowledgements
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